Edition:
United States

Galmed Pharmaceuticals Ltd (GLMD.OQ)

GLMD.OQ on NASDAQ Stock Exchange Capital Market

15.02USD
19 Jul 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$15.02
Open
--
Day's High
--
Day's Low
--
Volume
12,161
Avg. Vol
122,440
52-wk High
$27.06
52-wk Low
$3.61

Chart for

About

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product candidate,... (more)

Overall

Beta: 2.79
Market Cap(Mil.): $292.92
Shares Outstanding(Mil.): 20.91
Dividend: --
Yield (%): --

Financials

  GLMD.OQ Industry Sector
P/E (TTM): -- 214.53 33.05
EPS (TTM): -0.99 -- --
ROI: -88.91 -3.67 13.17
ROE: -91.54 -5.61 15.10

BRIEF-Galmed Pharmaceuticals Q1 Loss Per Share $0.17

* GALMED PHARMACEUTICALS PROVIDES BUSINESS UPDATE AND REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

May 09 2018

BRIEF-Galmed Pharmaceuticals To Report First Quarter 2018 Financial Results And Provide Business Update On Wednesday, May 9

* GALMED PHARMACEUTICALS TO REPORT FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDE BUSINESS UPDATE ON WEDNESDAY, MAY 9 Source text for Eikon: Further company coverage:

May 01 2018

BRIEF-Galmed Pharmaceuticals Announces Pricing Of $6 Mln Registered Direct Offering

* ANNOUNCES PRICING OF $6.0 MILLION REGISTERED DIRECT OFFERING

Apr 03 2018

BRIEF-Galmed Pharmaceuticals Files For Mixed Shelf Of Upto $150 Mln

* GALMED PHARMACEUTICALS LTD FILES FOR MIXED SHELF OF UPTO $150 MILLION - SEC FILING Source text: [https://bit.ly/2G8U5GO] Further company coverage:

Mar 26 2018

BRIEF-Galmed Pharmaceuticals Q4 Loss Per Share $0.27

* GALMED PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

Mar 13 2018

BRIEF-Galmed Announces Arrive Study Data

* TOP-LINE RESULTS FROM ARRIVE TRIAL DID NOT MEET ITS PRIMARY ENDPOINT

Feb 14 2018

BRIEF-Galmed Pharmaceuticals To Provide Corporate Update At The Leerink Partners 7Th Annual Global Healthcare Conference

* GALMED PHARMACEUTICALS TO PROVIDE CORPORATE UPDATE AT THE LEERINK PARTNERS 7TH ANNUAL GLOBAL HEALTHCARE CONFERENCE Source text for Eikon: Further company coverage:

Feb 08 2018

BRIEF-Israeli Tax Authority Issues Tax Ruling On Galmed Pharma's Unit

* GALMED PHARMACEUTICALS -ISRAELI TAX AUTHORITY ISSUED TAX RULING GRANTING CO'S UNIT "PREFERRED TECHNOLOGICAL ENTERPRISE" STATUS, SUBJECT TO CONDITIONS

Feb 07 2018

Earnings vs. Estimates